Metabolomic approaches to phenotype characterization and applications to complex diseases

被引：67

作者：

Oresic, Matej

Vidal-Puig, Antonio

Hanninen, Virve

机构：

[1] VTT Tech Res Ctr Finland, FIN-02044 Espoo, Finland

[2] Zora Biosci Ltd, FIN-02044 Espoo, Finland

[3] Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem & Metab Med, Cambridge CB2 2QR, England

[4] Orion Pharma, Clin Res & Dev, FIN-02101 Espoo, Finland

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2006年 / 6卷 / 04期

基金：

英国医学研究理事会;

关键词：

biomarker; critical path research; metabolomics; pharmacology; quantitative disease model; systems biology; toxicology; translational path research;

D O I：

10.1586/14737159.6.4.575

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Metabolites are the key regulators of systems homeostasis. As such, concentration changes of specific groups of metabolites may reflect systemic responses to environmental, therapeutic or genetic interventions. Thus, the study of metabolites is a powerful tool for the characterization of complex phenotypes as well as for the development of biomarkers for specific physiological responses. Therefore, metabolomics is a valuable platform for studies of complex diseases and the development of new therapies, both in nonclinical disease model characterization and clinical settings.

引用

页码：575 / 585

页数：11

共 67 条

[61]

U. S. Food and Drug Administration, 2004, INN STAGN CHALL OPP

[62] Innovation -: Rescuing drug discovery:: in vivo systems pathology and systems pharmacology [J].